Concomitant Mitral Valve Surgery in a Modified Morrow Procedure in Patients with Hypertrophic Obstructive Cardiomyopathy

Ventricular septal myectomy (modified Morrow procedure) is the gold standard surgical intervention for hypertrophic obstructive cardiomyopathy (HOCM). However, the indications for a concomitant mitral valve (MV) procedure to relieve mitral regurgitation (MR) or intrinsic MV pathological changes remain controversial. We aimed to retrospectively analyze this series of patients to evaluate the safety and efficiency of the procedure at our center.We retrospectively reviewed a total of 56 consecutive patients with HOCM who underwent concomitant MV surgery with modified Morrow procedures at our center between January 2019 and December 2021. The baseline characteristics, perioperative data, and postoperative outcomes were examined.The operative mortality rate was 0% among all 56 patients. Two patients had complete atrioventricular block, two patients experienced renal failure, and one patient required reoperation for bleeding. The peak gradient of the left ventricular outflow tract decreased from 93.6 ± 34.4 mm Hg to 20.5 ± 13.0 mm Hg. MR was significantly relieved, and the systolic anterior motion of the MV resolved completely after concomitant MV surgery. During a mean follow-up of 13.8 ± 7.1 months, no patient required cardiac reoperation.Concomitant surgery of the MV during the modified Morrow procedure was performed safely and effectively in the treatment of most types of HOCM in our practice.